InvestorsHub Logo

farrell90

01/16/18 6:57 PM

#213096 RE: Citrati #213051

Leo sounds confident a partnership deal will be reached

Audio also projects confidence.

7:34 Leo discusses IPIX strategy:

Select key programs for continued internal development.
Maximize value of current assets
It is definitely past time for partnership
This is how we will move all of this forward
It makes a lot of sense and it is built on the foundation of good results

28:00

Last 1 to 1.5 years what we have done is to broaden our drug candidates to a value inflection...Brillacidin anchored with Oral mucositis ...also[potential for] IBD...skin structures...Kevetrin... and Prurisol

Over this year talking to a lot of people not only here but at other get togethers...trying to leverage all of this with partnering opportunities...

Good luck, Farrell

Posted by Citrati

From one paragraph of the PR.

"In particular, Brilacidin-OM received an exceptional degree of attention at the San Francisco shows, further adding to an already robust partnering matrix. Innovation is developing Brilacidin-OM under a FDA Fast Track designation as a novel therapeutic and recently met the primary endpoint in a Phase 2 trial for preventing severe OM as well as a key secondary endpoint by delaying the onset of severe OM. Brilacidin has effectively earned a leadership position as an easily-delivered oral rinse drug candidate in OM—what many analysts predict will become a $1 billion market opportunity within the next few years.

From the next paragraph.

“What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”

And Finally this.
" The Company has begun exploring patient-friendly improvements to drug delivery (the use of sachets) and will be meeting with the FDA to determine next steps in the clinical development of Brilacidin-OM."


IMO there are individual treatments, there are platforms and there is delivery.
While the company stated " In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
I do not conclude that there is needed sequence. My thoughts are that a deal will be predicated upon and concluded when management believes the company will receive fair value. IMO that could happen independently from working with the FDA on the sachet delivery method. It all depends on the competing suitors and what offer is accepted whether it be for a platform or single target.

Merely my opinion.
Green Trades